CALA Calithera Biosciences, Inc.

11.15
0  -3%
Previous Close 11.55
Open 11.50
Price To book 4.98
Market Cap 305.79M
Shares 27,425,000
Volume 234,367
Short Ratio 2.16
Av. Daily Volume 1,011,640

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 enrolment commenced August 2016. Initial data due 2H 2017.
CB-839 + nivolumab
Renal cell carcinoma, malignant melanoma and non-small cell lung cancer

Latest News

  1. CB-1158 Phase I Data Accepted for an Oral Presentation at the ASCO Annual Meeting
  2. Zacks.com featured highlights: Calithera Biosciences, Weibo, Genco Shipping & Trading, Everi Holdings and Willdan Group
  3. Q1 Roundup: Winners and Losers of Biotech Sector
  4. Best ETFs & Stocks from Top Sectors of Q1
  5. Calithera Biosciences to Present at the 16th Annual Needham Health Care Conference
  6. Calithera to Receive $12 Million Milestone Payment From Incyte for Achievement of Pharmacokinetic and Pharmacodynamic Goals in Phase 1 Study
  7. Calithera Biosciences, Inc. Announces Closing of Public Offering and Exercise in Full of Option to Purchase Additional Shares
  8. Calithera Biosciences, Inc. Prices Public Offering of 6,830,000 shares of Common Stock
  9. Calithera Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock
  10. Edited Transcript of CALA earnings conference call or presentation 16-Mar-17 5:30pm GMT
  11. Calithera reports 4Q loss
  12. Calithera Biosciences Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Highlights
  13. Calithera Biosciences (CALA) Rises: Stock Moves Up 19.3%
  14. Calithera Biosciences to Report Fourth Quarter and Year-End 2016 Financial Results on Thursday, March 16, 2017
  15. Biotech Bounce Set to Pick Up Steam
  16. Calithera Biosciences to Present at Cowen and Company 37th Annual Health Care Conference
  17. Calithera Biosciences to Present at the BIO CEO & Investor and Leerink Global Healthcare Conferences in February
  18. Calithera Biosciences Inc (CALA): What You Need To Know
  19. Incyte Pays $53M for Calithera’s Oncology Drug
  20. Incyte and Calithera Enter into Deal for Oncology Candidate